Form 4: Arrowhead Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

A director at Arrowhead Pharmaceuticals, Adeoye Olukotun, sold 959 shares of common stock at $21 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Adeoye Olukotun, a director at Arrowhead Pharmaceuticals, sold 959 shares of common stock on January 23, 2025.
• The sale was executed at a price of $21 per share.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan.
• Following the transaction, Olukotun beneficially owns 35,781 shares of common stock, which includes shares underlying restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan. It is neither particularly positive nor negative.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. The use of 10b5-1 plans is a legal way for insiders to sell shares while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Sales by directors are a normal part of corporate activity, and the use of a 10b5-1 plan is a common practice to avoid insider trading concerns.
• The volume of shares sold is relatively small compared to the total outstanding shares of Arrowhead Pharmaceuticals, suggesting it is not a major event.
• Other pharmaceutical companies also have directors who sell shares under similar plans, so this is not unusual.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect given the small volume and the use of a 10b5-1 plan.

Key Dates

Keywords

insider trading, Form 4, 10b5-1 plan, stock sale, director, ARWR, Arrowhead Pharmaceuticals, equity securities